Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02YQO
|
||||
| Former ID |
DNC004411
|
||||
| Drug Name |
SCH-442416
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Phase 1 | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H19N7O2
|
||||
| InChI |
InChI=1S/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24)
|
||||
| InChIKey |
AEULVFLPCJOBCE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
15700772, 22957973, 29215552, 40960041, 77737929, 85787661, 103375076, 103991936, 127396092, 134223394, 134341616, 135697652, 160830068, 162023455, 162223704, 163094382, 163394401, 163842836, 172873496, 178100324, 189614611, 204418666, 223532855, 227238107, 241070384, 249492309, 249820076, 252156533, 252160006, 252216283
|
||||
| Target and Pathway | |||||
| Target(s) | Adenosine A3 receptor | Target Info | Inhibitor | [3] | |
| Adenosine A2a receptor | Target Info | Inhibitor | [4] | ||
| Adenosine A1 receptor | Target Info | Inhibitor | [4] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholismhsa04022:cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolismR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| Monoamine Transport | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00531193) Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3283). | ||||
| REF 3 | Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4. Epub 2010 Aug 10.Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. | ||||
| REF 4 | J Med Chem. 2000 Nov 16;43(23):4359-62.Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.